Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor

A combination product comprising:

• (i) a compound of formula (I), a pharmaceutically acceptable salt or a solvate thereof:
• in which:
• Y1 represents a halogen, a Ra, or Ga-Ra group;
• A represents a CH═CH or a CH2—CH2 group;
• Y2 represents a Gb-Rb group;
• Ga and Gb, identical or different, represent an atom of oxygen or sulfur;
• Ra represents a hydrogen atom, an unsubstituted (C1-C6)alkyl group, a (C6-C14)aryl group or a (C1-C6)alkyl group that is substituted by one or more halogen atoms, a (C1-C6)alkoxy or a (C1-C6)alkylthio group, (C3-C14)cycloalkyl groups, (C3-C14)cycloalkylthio groups or heterocyclic groups;
• Rb represents a (C1-C6)alkyl group substituted by at least a —COORc group, wherein Re represents a hydrogen atom, or a (C1-C6)alkyl group that is substituted or not by one or more halogen atoms, (C3-C14)cycloalkyl groups, or heterocyclic groups;
• and
• Y4 and Y5, identical or different, representing a (C1-C6)alkyl group that is substituted or not by one or more halogen atoms, (C3-C14)cycloalkyl groups or heterocyclic groups.
• and
• (ii) an ACC inhibitor.